Industry

DUBLIN–(BUSINESS WIRE)–The “Global Electronic Bone Growth Stimulator Market (2022-2027) by Product, Application, End-Users, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global Electronic Bone Growth Stimulator Market is estimated to be USD 511.31 Mn in 2022 and is expected to reach USD 715.13 Mn … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Global Cervical Dysplasia Market (2022-2027) by Diagnostics Type, Treatment Type, End-users, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis” report has been added to ResearchAndMarkets.com’s offering. The Global Cervical Dysplasia Market is estimated to be worth USD 704.34 million in 2022, and is expected to reach USD 977.76 million by … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “WEGOVY (Semaglutide), Drug Insight and Market Forecast – 2032” report has been added to ResearchAndMarkets.com’s offering. This report provides comprehensive insights about WEGOVY (Semaglutide) for Obesity in the 7MM. A detailed picture of the WEGOVY (Semaglutide) for Obesity in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), … [Read more…]

Dominican University New York, King University and Thomas Jefferson University recognized for commitment to improving nursing education NEW YORK–(BUSINESS WIRE)–#edchat–Nursing shortages and burnout remain an ongoing problem for the healthcare community, with 80 percent of nurses saying their units are inadequately staffed. To help solve for the shortages Nurse.org’s State of Nursing Report recommends, among … [Read more…]

PALM SPRINGS, Calif.–(BUSINESS WIRE)–Onshoring pharmaceutical manufacturing has become a priority in the United States and is even backed by a $2 billion federal investment. Manufacturing capacity, according to a recent report, is readily available. SmartSkin Technologies announced Martin VanTrieste has joined its Board of Directors to offer his unique insights on how to maximize pharmaceutical … [Read more…]

RICHMOND, Va.–(BUSINESS WIRE)–Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announces that its program Adimune™ has initiated the GMP manufacturing of drug candidate ADI™-100 as a key milestone toward its goal to begin first-in-human trials during … [Read more…]

Shows potential for CD8+ T cell targeted immunotherapy for chronic viral infections SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infections and autoimmune disorders, today announced that it will present the first preclinical data for AB359, … [Read more…]

LOS ALTOS, Calif.–(BUSINESS WIRE)–RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform, today announced that the Company’s CEO, Shaun Bagai, will participate in a ROTH Capital Partners Deep Dive webinar on Thursday, October 27th at 1 p.m. ET. To … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “DNA Diagnostics Market” report has been added to ResearchAndMarkets.com’s offering. A recent market study published on DNA Diagnostics offers a global industry analysis for 2015-2021 and opportunity assessment for 2022-2032. The study offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical and current growth parameters, … [Read more…]

Positive Phase 1 Data Support Near-term Initiation of Global Phase 2 Trial CAMBRIDGE, Mass. & LAUSANNE, Switzerland–(BUSINESS WIRE)–Anokion SA, a clinical-stage biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that data from the Phase 1 ACeD (Assessment of KAN-101 in Celiac Disease) clinical trial evaluating its lead candidate, KAN-101, … [Read more…]